Ebbu Announces Groundbreaking Scientific Research of "Entourage Effect"

Ebbu conducts never-before-published research on the effects of cannabinoids and terpenes on receptors in the body

DENVER--()--Ebbu continues to push the boundaries of cannabis science with the announcement today of significant new discoveries, never published in the cannabis research literature. Ebbu has built a state-of-the-art cellular pharmacology drug discovery lab with a poly-pharmaceutical approach in order to understand how the different compounds of cannabis work in concert with each other on the mind and body.

"Once again Ebbu is forging new frontiers. Our cellular pharmacology discovery lab is testing individual and combinations of cannabinoids and terpenes on cannabinoid receptors and other targets that interact closely with the endocannabinoid system," said Jon Cooper, founder and CEO of Ebbu.

Since the late 1990s, thanks to the pioneering research of Raphael Mechoulam and many others, it's been understood that the building blocks of cannabis (cannabinoids and other compounds) have a greater effect on the body together than when separated into individual compounds. It's called the "entourage effect." However, little has been known about exactly how the entourage effect works because, until recently, study in the US has been stymied by the near complete legal prohibition on marijuana and because most international studies have been focused on individual cannabinoids.

"Think of the effect when you combine chocolate and peanut butter; you experience a third taste. The endocannabinoid system works essentially the same way," remarked Cooper. "We are studying different compounds that when combined will deliver desirable experiences. We believe this groundbreaking work will result in the most consistent and predictable products in the industry."

"Ebbu has completed the initial pharmacological fingerprinting of CB1 and has nearly completed its analysis of TRPV1,” said Brian Reid, chief scientist at Ebbu. Cannabinoid receptor 1, or CB1, is recognized as the cannabinoid receptor responsible for the main psychoactive effect of cannabis, and TRPV1, the transient receptor potential cation channel subfamily V member 1, also known as the capsaicin receptor and the vanilloid receptor 1, is a very important target for the perception of pain. Mr. Reid further stated, "Our findings are remarkable. We have identified 11 compound combinations that have synergistic or other notable effects on these two receptors."

Specifically, Ebbu has found:

  • 6 terpenes that moderately increase potency of THC at CB1
  • 2 terpenes that strongly increase the potency of THC at CB1
  • 2 cannabinoids that moderately increase the effect of THC
  • 1 cannabinoid that has a unique interaction with THC. It's both an antagonist and intensifies the effect of THC at CB1.

In addition, Ebbu has uncovered significant results on TRPV1, which is a very important target for the perception of pain. Ebbu found one terpene that synergizes with THC at TRPV1. Our research will continue examining other combinations of cannabinoids and terpenes.

This research is a significant milestone toward the development of Ebbu's flagship Feelings line that will enable consumers to choose a desired experience when using our Feelings line products, such as Chill, Energy, Create and Bliss, which are planned for launch in 2017.

About Ebbu LLC

Founded in 2013, Ebbu LLC, a Colorado limited liability company, is a disruptive cannabis research, development, and distribution start-up inspired by a simple idea: making cannabis predictable, consistent, and reliable so it can be enjoyed by everyone (who’s legally able to, of course). With a state-of-the-art science lab run by a highly advanced team of Ph.D. scientists, Ebbu is breaking ground on creating a new kind of cannabis experience – one of discovery & enjoyment. At the core of this company is its mission: to unlock the potential of cannabis to enhance and improve people’s lives.

Forward-Looking Statements

This press release contains forward-looking statements, which are, by their nature, subject to risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements that are forward-looking by reason of context, words such as "may", "will", “strives”, "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", “towards” or "continues" and similar expressions may identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to: Ebbu’s future performance, research efforts, consumer experiences, product launch dates, and expansion efforts. Important factors that, in Ebbu’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include changes in Federal and state laws and regulations, changes in the policies of governments, changes in public perception of the marijuana industry, Ebbu’s access to sufficient funds and capital to continue its efforts, market acceptance of Ebbu’s products, and changing levels of competition in Ebbu’s markets and other matters beyond the control and/or prediction by Ebbu.

All statements contained in this press release (not limited to forward looking statements) speak only as of the date of this press release, and Ebbu expressly disclaims any obligation to update or revise any such any statement, whether as a result of future events, new information or otherwise.


Matthew Moseley, 303-887-0826


Matthew Moseley, 303-887-0826